NanoPAMDA enables rapid PAM characterization of metagenome-derived Cas9 effectors
- 1Department of Molecular Biology and Genetics, Faculty of Science, Bogazici University
Abstract
CRISPR-Cas9 orthologs remain functionally underexplored despite the rapidly growing scale of publicly available metagenomic sequencing data. Here, we applied a multi-stage computational discovery pipeline to two independent sources of metagenomic sequence data, a multi-biome collection of 660,185 metagenome-assembled genomes spanning 17 public catalogs, and raw sequencing reads from human microbiome studies assembled de novo, to identify novel Cas9 orthologs. Candidates were filtered for guide RNA architectural plausibility, sequence novelty, conservation of catalytic residues, and structural integrity, yielding 14 candidates spanning both data sources for experimental characterization. To determine PAM preference at scale, we developed a cost-effective Nanopore long-read-based adaptation of the high-throughput PAM determination assay (NanoPAMDA), enabling rapid, time-resolved, kinetic PAM profiling across many candidates in parallel. One Cas9 effector, E10, showed PAM-specific activity in vitro and was catalytically active in E. coli. Together, these findings demonstrate a scalable, long-read sequencing-based framework for discovering and biochemically characterizing novel Cas9 orthologs from metagenomic data.
Related
- Comparative characterization of the mucosal eukaryotic virome across independent whole-metagenome shotgun sequencing cohorts
- An engineered α-1,3-glucanase-derived probe enables sensitive detection of α-1,3-glucan and reveals its soluble release by Aspergillus
- Prime editing enables high-throughput identification and characterization of selective MutSβ inhibitors
- Hierarchical distribution matching enables comprehensive characterization of common and condition-specific cell niches in spatial omics data
- A phage-derived promoter SD13 enables strong and cross-host gene expression in Streptomyces and Escherichia coli.
BibTeX
@misc{genel2026nanopamda,
title = {{NanoPAMDA enables rapid PAM characterization of metagenome-derived Cas9 effectors}},
author = {I. Genel and C. Suren and I. C. Kurt},
howpublished = {bioRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.04.764188},
url = {https://www.biorxiv.org/content/10.64898/2026.11.04.764188v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - NanoPAMDA enables rapid PAM characterization of metagenome-derived Cas9 effectors
AU - I. Genel
AU - C. Suren
AU - I. C. Kurt
PY - 2026
DA - 2026/11/04
PB - bioRxiv
DO - 10.64898/2026.11.04.764188
UR - https://www.biorxiv.org/content/10.64898/2026.11.04.764188v1
AB - CRISPR-Cas9 orthologs remain functionally underexplored despite the rapidly growing scale of publicly available metagenomic sequencing data. Here, we applied a multi-stage computational discovery pipeline to two independent sources of metagenomic sequence data, a multi-biome collection of 660,185 metagenome-assembled genomes spanning 17 public catalogs, and raw sequencing reads from human microbiome studies assembled de novo, to identify novel Cas9 orthologs. Candidates were filtered for guide RNA architectural plausibility, sequence novelty, conservation of catalytic residues, and structural integrity, yielding 14 candidates spanning both data sources for experimental characterization. To determine PAM preference at scale, we developed a cost-effective Nanopore long-read-based adaptation of the high-throughput PAM determination assay (NanoPAMDA), enabling rapid, time-resolved, kinetic PAM profiling across many candidates in parallel. One Cas9 effector, E10, showed PAM-specific activity in vitro and was catalytically active in E. coli. Together, these findings demonstrate a scalable, long-read sequencing-based framework for discovering and biochemically characterizing novel Cas9 orthologs from metagenomic data.
ER -